Social, economic, and health utility considerations in the treatment of overactive bladder

Abstract

Overactive bladder (OAB) is a highly prevalent urinary syndrome with a profound impact on quality of life (QoL) of affected patients and their family because of its adverse effects on social, sexual, interpersonal, and professional function. Cost-of-illness analyses showed the huge economic burden related to OAB for patients, public healthcare systems, and society, secondary to both direct and indirect costs; however, intangible costs related to QoL impact are usually omitted from these analyses. Recently many novel treatment modalities have been introduced and the need to apply the modern methodology of health technology assessment to these treatment strategies was immediately clear in order to evaluate objectively their value in term of both improvement in length/quality of life and costs. Health utilities are instruments that allow a measurement of QoL and its integration in the economic evaluation using the quality-adjusted life-years model and cost-utility analysis. The development of suitable instruments for quantifying utility in the specific group of OAB patients is vitally important to extend the application of cost-utility analysis in OAB and to guide healthcare resources allocation for this disorder. Studies are required to define the cost-effectiveness of available pharmacological and nonpharmacological therapy options for this disorder.

The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta‐analysis

“…The following information was collected for each study: (1) the name of the RCT; (2) the study design and sample size; (3) the therapy that the patients received; (4) the country in which the study was conducted; and (5) data including the daily frequency of urinary incontinence (UI) became completely continent, the mean number of UI per day, the mean number of micturitions per day, maximum cystometric capacity (MCC), postvoid residuals (PVR), urinary tract infections (UTI), and clean intermittent catheterization (CIC).…”

“…Overactive bladder (OAB), defined by the International Continence Society as urgency with or without urinary incontinence, usually associated with frequency and nocturia, 1 is a multifactorial and common health disorder associated with detrimental effects on quality of life and huge economic burden. 2,3 The prevalence of OAB is approximately 12-19% in both men and women. [4][5][6] Antimuscarinic agents are the current pharmacological mainstay for OAB.…”

Mirabegron: a review of recent data and its prospects in the management of overactive bladder

“…Overactive bladder (OAB), defined by the International Continence Society as urgency with or without urinary incontinence, usually associated with frequency and nocturia [Abrams et al 2002], is a multifactorial and common health disorder associated with detrimental effects on quality of life and huge economic burden [Irwin et al 2006;Sacco et al 2010]. Irrespective of the pathophysiology, the aim of treatment of OAB is to obtain symptom relief without affecting the empty phase of the micturition cycle.…”

Modern Possibilities of Medical Treatment of Overactive Bladder in Women

“…Молекула мирабегрона была разработана японскими учеными и изначально имела условное название YM178 [26]. Первые пилотные исследования по применению β-адреномиметиков были инициированы в 1980-х гг.…”